Arguably the most exciting emerging treatment in immunotherapy, personalized medicine has provided increasing hope and understanding in targeting different cancers by incorporating genetic and data-driven approaches.
In this latest installment from the TIDES eBook Series, we look at the milestones and challenges encountered by today’s leading researchers in the journey of producing personalized vaccines and therapies, including antigen selection and synthesis, machine-learning and regulatory considerations.
Read or download the report above (or click here).
Features include:
- The Future of Peptide Vaccines and Personalized Peptide Therapies: This whitepaper provides an overview of peptide cancer and infectious disease vaccines, including development within the industry and regulatory view of personalized medicine concepts.
- Building Better Personal Cancer Vaccines: We explore how effective anti-tumor immunity in humans has been associated with the presence of T-cells directed at cancer neoantigens, as presented by Dr. Catherine J. Wu, Professor of Medicine at Dana-Farber Cancer Institute.
- Peptide Neoantigen Cancer vaccines and T Cell Therapy: We look at precision antigen selection carried out with a personalized immune response profiling platform demonstrated by Dr. Daniel deOliveira from Genocea Biosciences at TIDES: Oligonucleotide and Peptide Therapeutics.
- High throughput GMP neoantigen peptide synthesis brings individualized cancer immunotherapy to a new level: This whitepaper from Gyros Protein Technologies examines the growing demand on GMP peptide synthesis for the production of neoantigen-based cancer therapies and the methods to address it.
- Personal Neoantigen-Based Cancer Vaccine NEO-PV-01 in the Treatment of Metastatic Cancers: We look at the latest overview of the personalized neoantigen cancer vaccine NEO-PV-01, presented by Dr. Jesse Dong, Vice President, Peptide Chemistry at BioNTech.
- Neoantigen Peptide Therapies: An Interview with Samantha Zaroff Ph.D, Genscript: Dr. Samantha Zaroff Ph.D of Genscript discusses the use of neoantigens in personalised medicine and the challenges behind producing them.